UBS AM’s Aprea Therapeutics APRE Stock Holding History

UBS AM’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,135	Closed	-$116K	–	2753
2021 Q1	$116K	Buy	+1,135	New	+$132K	﹤0.01%	2588

Other funds holding APRE

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return

PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

UBS AM's APRE Position: Q2 2021 in Review

UBS AM sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 1,135 shares — an estimated $116K sold.

UBS AM first reported a position in APRE in Q1 2021 and held it in 1 quarter. The position peaked at $116K in Q1 2021. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

UBS AM reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
UBS AM sold 1,135 Aprea Therapeutics shares in Q2 2021, an estimated $116K.
UBS AM first reported a position in Aprea Therapeutics in Q1 2021 and held it in 1 quarter.
UBS AM's Aprea Therapeutics position peaked at $116K in Q1 2021.
50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on UBS AM's 13F filing for Q2 2021, filed 16 Aug 2021.